Dr. Lal PathLabs Limited has issued a regulatory disclosure under Regulation 30 of the SEBI Listing Regulations regarding the mandatory transfer of unclaimed equity shares to the Investor Education and Protection Fund (IEPF).

Regulatory Compliance Notice

The company published newspaper advertisements in Financial Express and Jansatta on March 19, 2026, notifying equity shareholders about unclaimed shares related to the final dividend from Financial Year 2018-19. This disclosure was made pursuant to Regulation 30 & 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

IEPF Transfer Requirements

Under Section 124(6) of the Companies Act, 2013, read with IEPF Authority (Accounting, Audit, Transfer and Refund) Rules, 2016, equity shares corresponding to dividends that remain unclaimed for seven consecutive years are mandated to be transferred to the demat account of the IEPF Authority.

Shareholder Communication

The company has undertaken comprehensive communication efforts to notify affected shareholders:

• Individual notices/letters sent to concerned shareholders through speed post
• Communications sent to latest addresses available with the Company/Depositories
• Shareholder details displayed on the company website at www.lalpathlabs.com
• Newspaper advertisements published for wider reach

Action Required from Shareholders

Shareholders who have not claimed their dividend since Financial Year 2018-19 (Final Dividend) are requested to claim their unclaimed dividend amounts on or before May 31, 2026. Applications must be made to the Company and/or its Registrar and Share Transfer Agent (RTA), MUFG Intime India Private Limited.

Important Disclaimers

The company has clarified that no claim shall lie against Dr. Lal PathLabs Limited or its RTA regarding individual amounts, shares, and other benefits transferred to the IEPF. However, shareholders can claim their unclaimed dividends and shares already transferred to IEPF by following procedures stipulated in the IEPF Rules.

Contact Information

For further information or clarification, shareholders may contact:

• Company: Email at cs@lalpathlabs.com
• RTA: MUFG Intime India Private Limited at Noble Heights, 1st Floor, Plot NH-2, C-1, Block, LSC near Savitri Market, Janakpuri, New Delhi-110058
• RTA Contact: Tel: 011-41410592, Email: iepf.shares@in.mps.muf.com

The disclosure was signed by Vinay Gujral, Company Secretary & Compliance Officer, and is effective from March 19, 2026.

Dr. Lal PathLabs Limited has announced the completion of the voluntary liquidation process for its wholly owned subsidiary, Suburban Diagnostics (India) Private Limited. The National Company Law Tribunal (NCLT) Mumbai Bench has approved the dissolution through an order reserved on February 27, 2026, which was received by the liquidator on March 9, 2026.

NCLT Approval and Timeline

The tribunal's order formally dissolves Suburban Diagnostics under Section 59(8) of the Insolvency and Bankruptcy Code, 2016. The liquidation process began with board approval on February 6, 2025, when directors passed a Declaration of Solvency affirming the company's ability to pay all debts from asset proceeds.

Subsidiary Financial Contribution

Suburban Diagnostics made significant contributions to the consolidated entity before liquidation. As of March 31, 2024, the subsidiary's financial parameters demonstrated its operational scale within the group structure.

Liquidation Process Details

The voluntary liquidation followed established legal procedures under the Insolvency and Bankruptcy Code, 2016. Shareholders approved the liquidation through a Special Resolution in an Extraordinary General Meeting held on February 6, 2025, appointing Mr. Dilipkumar Natvarlal Jagad as the liquidator.

The liquidator conducted public announcements on February 8 and 9, 2025, in 'Active Times' and 'Mumbai Lakshwadeep' newspapers, inviting stakeholder claims. All admitted claims were settled, and assets were realized and distributed according to regulatory requirements.

Business Consolidation Impact

Suburban Diagnostics was incorporated on June 6, 2002, and operated pathology and diagnostic centers in Maharashtra. The entire business undertaking was distributed by the liquidator, with operations consolidating into Dr. Lal PathLabs with effect from March 18, 2025.

The NCLT noted that the voluntary liquidation process was completed with no outstanding liabilities against the corporate entity. The liquidator closed all bank accounts, including the voluntary liquidation account with NIL balance on February 17, 2026.

Regulatory Compliance

Dr. Lal PathLabs has fulfilled all disclosure requirements under Regulation 30 of SEBI Listing Regulations and related circulars. The company confirmed this transaction does not constitute a sale of undertaking but represents a voluntary liquidation process for business consolidation purposes.